Pelacarsen didn’t protect heart health despite lowering levels of a protein particle, “Lp(a),” in a large clinical trial — a ...

What's possible when AI models can learn from additional health data modalities to create a more complete understanding of ...

The drugmaker is leaning on a better side effect profile compared to drugs from J&J, Pfizer and Regeneron as it pushes ...

Side effects observed in testing have led Novartis to halt development of rap-cel in multiple indications and Bristol Myers ...

The failure of what was once considered a potential blockbuster therapy represents a major setback in a tough-to-treat ...

Deals with Chinese drugmakers are continuing at a steady pace, while two mid-cap biotechs' stock prices took a tumble this ...

At a big meeting for cardiovascular medicines, Cytokinetics and Arrowhead aimed to separate their drugs from competitors ...

The clearance and broader-than-expected label for Mimrylo open up a yearly revenue opportunity for Takeda that some analysts ...

A new data cut of a trial pitting ivonescimab, a bispecific antibody, against Merck’s Keytruda showed the new drug helped ...

The company is now hoping for an affirmative answer on its application after an unusually turbulent year dealing with U.S.

Not only is the XBI continuing to hover around a historic high, but drug companies can’t seem to get enough of both large IPOs and big-ticket M&A.

Results published in NEJM raised questions about the benefits “silencer” medications provide on top of standard therapies for ...